What is the Fiscal Year for Aadi Bioscience?
Date: November 13, 2026
Aadi Bioscience's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Los Angeles, California
Industry
Biotechnology Research
Stock Symbol
AADI
Website
https://aadibio.com/Description
Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). In March 2025, we became a wholly-owned subsidiary of KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan. A science-first mindset and patient-centric approach is always in our genes. Together with KAKEN, we continue to dedicate to developing products for cancers with mTOR pathway driver alterations. For more information, please visit: https://aadibio.com/ and https://www.kaken.co.jp/english/.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Aadi Bioscience and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.